[Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors].
Treatment of inflammatory bowel disease (IBD) with antibodies against tumour necrosis factor-alpha (TNF) is effective. Not all patients respond, however, and the effect wears off in a considerable fraction of initial responders over time. Individual differences in bioavailability, pharmacokinetics and immunogenicity are now recognized as essential problems in the use of biologicals, and blood measurements of functional anti-TNF antibodies and antibodies against anti-TNF drugs with robust and clinically relevant methods may optimize treatment of IBD through individualized therapeutic regimens.
Steenholdt
Casper
C
Herlev Hospital, Institut for Inflammationsforskning, IIR7521, Rigshospitalet, DK-2100 København Ø, Denmark.
Ainsworth
Mark
M
Thomsen
Ole Østergaard
OØ
Brynskov
Jørn
J
Bendtzen
Klaus
K
D000893:Anti-Inflammatory Agents / Q000097:blood / Q000276:immunology / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000906:Antibodies / Q000097:blood; D000911:Antibodies, Monoclonal / Q000097:blood / Q000276:immunology / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001682:Biological Availability; D003424:Crohn Disease / Q000097:blood / Q000188:drug therapy / Q000276:immunology; D016903:Drug Monitoring; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D000069285:Infliximab; D057285:Precision Medicine; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
D000893:Anti-Inflammatory Agents; D000906:Antibodies; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab